MorphoSys AG engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation. The company was founded in 1992 and is based in Planegg, Germany.
MOR Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for MOR, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that MorphoSys AG ranked in the 0th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for MorphoSys AG ended up being:
The stock's equity weight, or the proportion of capital from equity relative to debt, is 59. Notably, its equity weight is greater than just 15.73% of US equities in the Healthcare sector yielding a positive free cash flow.
The company's compound free cash flow growth rate over the past 0.52 years comes in at -0.82%; that's greater than only 0.42% of US stocks we're applying DCF forecasting to.
MorphoSys AG's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than just 0% of US stocks with positive free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as MOR, try AGHC, ALC, AMRN, ATRS, and PACB.
MorphoSys AG (MOR) Q2 2020 Earnings Conference Call August 06, 2020, 08:00 AM ET Company Participants Anja Pomrehn - Head of IR Jean-Paul Kress - CEO Jens Holstein - CFO Malte Peters - Chief Research and Development Officer Roland Wandeler - COO Conference Call Participants Jason Butler - JMP Securities...
MorphoSys' Management team will host a conference call and webcast on August 6, 2020 at 2:00pm CEST (1:00pm BST; 8:00am EDT) to present the second quarter and first half financial results 2020 and the further outlook for 2020.
The views expressed are her own.) As U.S. coronavirus cases hit records and reopenings are dialled back, Federal Reserve officials admitted economic growth forecasts from the June policy meeting did not factor in the risk of a second wave. Fed Governor Lael Brainard summed it up as "a thick fog of uncertainty" and said "downside risks predominate." A similar message from the corporate world -- Delta Airlines CEO Ed Bastian said the industry was "at a stall right now."
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / July 14, 2020 / MorphoSys AG (FSE:MOR); Prime Standard Segment; MDAX & TecDAX; (NASDAQ:MOR) announced today that its licensee Janssen Research & Development, ...